Asthma

Study Outline

This study is a Phase 3 clinical trial which aims to evaluate a potential new medicine for severe asthma and is not yet approved to treat patients with asthma.

GSK3511294 (also known as the study drug) is a type of medicine called a monoclonal antibody that is made in the laboratory. It works by blocking a specific protein in the body called interleukin-5 which is involved in the severity of asthma and inflammation of the lungs.

The study drug works the same way as three already approved asthma medications: mepolizumab, reslizumab, and benralizumab. These medications are taken every 4 to 8 weeks. However, it is hoped that the effect of the study drug will last over a longer period of time (once every 26 weeks).

To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

Eligibility & Requirements

• Aged 18 years and older
• Diagnosis of asthma
• Already on mepolizumab or benralizumab

What's Involved

• The trial will run for up to 15 months.
• During this period you will be required to attend up to 18 visits to the Institute for Respiratory Health at QEII Medical Centre in Nedlands.